Association between thyroid hormone T3 and aggression in drug-naïve schizophrenia: a directed acyclic graph analysis.

Authors

Cong Yao, Changyong Jiang, Meng Zhang, Qiao Su, Xiaoxiao Sun, Zhenning Feng, Boxuan Zhou, Meijuan Li, Yuying Qiu, Jie Li

Published in

European archives of psychiatry and clinical neuroscience. Jul 08, 2026. Epub Jul 08, 2026.

Abstract

Aggression is a major clinical issue in schizophrenia, but its biological basis remains unclear. This study examined the relationship between thyroid hormones, psychiatric symptoms, and aggression in drug-naïve schizophrenia (DNS) patients using causal inference methods.
In a case-control study, we examined 161 DNS patients and 63 healthy controls. Aggression was assessed with the Modified Overt Aggression Scale (MOAS) and psychiatric symptoms with the Positive and Negative Syndrome Scale (PANSS). Serum thyroid-stimulating hormone (TSH), triiodothyronine (T3), and thyroxine (T4) were measured. DAG modeling, multivariable regression, mediation, and sensitivity analyses were conducted to characterize the relationships among thyroid hormones, psychiatric symptoms, and aggression.
DNS patients exhibited significantly lower TSH levels than controls (t = - 24.81, p < 0.001). Within the schizophrenia cohort, the high-aggression group showed higher T3 levels (t = 2.24, p = 0.03) and more severe positive symptoms (t = 2.85, p < 0.001) than the low-aggression group. DAG analysis identified a direct association between T3 and aggression severity. In multivariable regression analyses, T3 remained significantly associated with aggression severity after adjustment for T4, age, and sex (β = 5.08, p = 0.01); and the association remained significant after further adjustment for positive and negative symptom dimensions (β = 4.99, p = 0.01). Mediation analyses found no evidence that positive or negative symptom dimensions explained this association. Sensitivity analyses supported the robustness of the findings.
Higher T3 levels were associated with greater aggression severity in patients with schizophrenia.

PMID:
42420552
Bibliographic data and abstract were imported from PubMed on 09 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.